凝血分析儀市場機會、成長動力、產業趨勢分析與 2025 - 2034 年預測

2024 年全球凝血分析儀市場規模達到 46 億美元，預計 2025 年至 2034 年期間複合年成長率將達到 6.1%。 推動這一成長的因素包括血友病和血栓等血液疾病發病率上升，以及久坐生活方式、人口老齡化和肥胖導致的心血管併發症增加。隨著預防保健意識的不斷增強以及早期診斷檢測的日益普及，凝血分析儀在醫療機構中的應用正在加速。

市場按產品類型細分為消耗品和儀器，預計消耗品將占主導地位。預計耗材部門的複合年成長率為 6.3%，到 2034 年將創下 55 億美元的產值。試劑技術的進步增強了與自動化系統的兼容性，提高了高通量測試環境的效率和精確度，進一步推動了需求。

根據測試類型，市場涵蓋凝血酶原時間 (PT) 測試、活化部分凝血活酶時間 (aPTT) 測試、D-二聚體測試、纖維蛋白原測試和其他測試。預計 PT 測試的複合年成長率將達到 6.6%，到 ​​2034 年將達到 26 億美元。它在常規和高級診斷程序中的關鍵作用凸顯了其對市場成長的重大貢獻。

在美國，凝血分析儀市場規模在 2024 年達到 15 億美元，預計到 2034 年將以 5.3% 的複合年成長率穩步成長。隨著有效監測抗凝血療法變得越來越重要，對凝血測試（尤其是 PT 和 aPTT）的需求持續上升。此外，臨床實驗室全自動化系統的整合正在提高工作流程效率，滿足大量檢測的需求，並鞏固該國的市場主導地位。

目錄

第 1 章：方法論與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 心血管和血液相關疾病盛行率不斷上升
    • 對即時診斷設備的需求不斷成長
    • 凝血分析儀的技術進步
    • 提高對早期疾病診斷的認知
  • 產業陷阱與挑戰
    • 設備核准的嚴格監管要求
    • 缺乏操作先進分析儀的熟練專業人員
• 成長潛力分析
• 監管格局
• 技術格局
• 差距分析
• 波特的分析
• PESTEL 分析
• 未來市場趨勢
• 價值鏈分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第 5 章：市場估計與預測：按產品類型，2021 年至 2034 年

• 主要趨勢
• 耗材
• 儀器

第6章：市場估計與預測：按模式，2021 – 2034 年

• 主要趨勢
• 自動化
• 半自動化
• 手動的

第 7 章：市場估計與預測：按測試類型，2021 年至 2034 年

• 主要趨勢
• 凝血酶原時間（PT）檢測
• 活化部分凝血活酶時間 (aPTT) 檢測
• D-二聚體檢測
• 纖維蛋白原檢測
• 其他測試類型

第 8 章：市場估計與預測：按技術，2021 年至 2034 年

• 主要趨勢
• 光學技術
• 電化學技術
• 機械技術
• 其他技術

第 9 章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 醫院
• 診斷實驗室
• 學術和研究機構
• 其他最終用戶

第 10 章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：公司簡介

• Abbott
• DiaSys
• Erba Mannheim
• HELENA LABORATORIES
• HemoSonics
• HORIBA
• iLine
• mindray
• RANDOX
• Roche
• SEKISUI
• SIEMENS Healthineers
• Stago
• sysmex
• werfen

The Global Coagulation Analyzers Market reached USD 4.6 billion in 2024 and is poised to grow at a robust CAGR of 6.1% from 2025 to 2034. This growth is fueled by a rising prevalence of blood disorders such as hemophilia and thrombosis, alongside an increase in cardiovascular complications driven by sedentary lifestyles, aging populations, and obesity. As awareness of preventive healthcare expands and early diagnostic testing gains traction, the adoption of coagulation analyzers across healthcare facilities is accelerating.

The market is segmented by product type into consumables and instruments, with consumables expected to dominate. Projected to grow at a CAGR of 6.3%, the consumables segment is anticipated to generate USD 5.5 billion by 2034. The consistent demand for reagents, calibrators, and other essential consumables underpins this growth, as diagnostic centers and laboratories rely heavily on these products for routine and specialized coagulation testing. Advancements in reagent technology are enhancing compatibility with automated systems, driving efficiency and precision in high-throughput testing environments, further fueling demand.

By test type, the market encompasses prothrombin time (PT) testing, activated partial thromboplastin time (aPTT) testing, D-dimer testing, fibrinogen testing, and other tests. PT testing is forecasted to achieve a CAGR of 6.6%, reaching USD 2.6 billion by 2034. This test is vital for diagnosing clotting disorders, monitoring anticoagulant therapies, assessing liver function, and detecting bleeding abnormalities. Its critical role in both routine and advanced diagnostic procedures underscores its significant contribution to market growth.

In the United States, the coagulation analyzers market reached USD 1.5 billion in 2024 and is projected to grow at a steady CAGR of 5.3% through 2034. The U.S. leads the North American market, benefiting from advanced healthcare infrastructure, substantial healthcare spending, and a high prevalence of chronic conditions like atrial fibrillation. The demand for coagulation tests, particularly PT and aPTT, continues to rise as effective monitoring of anticoagulant therapies becomes increasingly essential. Moreover, the integration of fully automated systems in clinical laboratories is enhancing workflow efficiency, meeting the needs of high-volume testing, and reinforcing the country's market dominance.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cardiovascular and blood-related disorders
    • 3.2.1.2 Growing demand for point-of-care diagnostic devices
    • 3.2.1.3 Technological advancements in coagulation analyzers
    • 3.2.1.4 Rising awareness about early disease diagnosis
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory requirements for device approval
    • 3.2.2.2 Lack of skilled professionals for operating advanced analyzers
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Gap analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends
• 3.10 Value chain analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Consumables
• 5.3 Instruments

Chapter 6 Market Estimates and Forecast, By Mode, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Automated
• 6.3 Semi-automated
• 6.4 Manual

Chapter 7 Market Estimates and Forecast, By Test Type, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Prothrombin time (PT) testing
• 7.3 Activated partial thromboplastin time (aPTT) testing
• 7.4 D-dimer testing
• 7.5 Fibrinogen testing
• 7.6 Other test types

Chapter 8 Market Estimates and Forecast, By Technology, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Optical technology
• 8.3 Electrochemical technology
• 8.4 Mechanical technology
• 8.5 Other technologies

Chapter 9 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Diagnostic laboratories
• 9.4 Academic and research institutes
• 9.5 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Abbott
• 11.2 DiaSys
• 11.3 Erba Mannheim
• 11.4 HELENA LABORATORIES
• 11.5 HemoSonics
• 11.6 HORIBA
• 11.7 iLine
• 11.8 mindray
• 11.9 RANDOX
• 11.10 Roche
• 11.11 SEKISUI
• 11.12 SIEMENS Healthineers
• 11.13 Stago
• 11.14 sysmex
• 11.15 werfen